Top searches

PL

Resources

B2RLaw advises Proteon Pharmaceuticals on a strategic partnership with Skretting

01/02/2021

B2RLaw has advised Proteon Pharmaceuticals on a strategic partnership with Skretting aimed at providing functional solutions to tackle health challenges in the aquaculture industry.

The companies will collaborate on developing products using bacteriophage technology to support aquaculture farmers as part of a holistic health strategy. The companies will work in a parallel R&D pipeline on the project.

The Partnership allows Proteon to grow its product portfolio in aquaculture and expand its presence worldwide. Both Proteon Pharmaceuticals and Skretting predict that the technology will become a valuable component of integrated management strategies on-farm with both feed and water applications under investigation.

Proteon Pharmaceuticals is a Polish originating biotech company with a vision to develop natural feed additives that help remove antibiotics from the food chain and improve animal and human health. The Company uses precision biology for microbiome protection to improve animal and human health, increasing environmental sustainability and eliminating the unnecessary use of antibiotics.

Norwegian company, Skretting is the world’s largest producer of feeds for farmed fish. The Company has operations on five continents and produces 2.5 million tonnes of feed annually, for more than sixty species of fish. Skretting has 3,500 employees worldwide. Skretting has an R&D unit known as Skretting Aquaculture Research Centre (ARC) with the main objective to provide research and technical support regarding fish and shrimp feed. It has 140 employees representing 25 nationalities.

B2RLaw’s team advising Proteon Pharmaceuticals was led by Partner George Havaris and included Counsels Paulina Wyrostek and Malwina Niczke – Chmura.

George Havaris advises, “Proteon Pharmaceuticals is a Polish company that is well on the path to being a global leader in its field of operation. Animal health is a little-known industry in the wider public eye. However, animal health is fundamental to the health and well-being of humans. We congratulate Proteon and Skretting on this exciting Partnership and we look forward to continuing our support to Proteon on its growth path”.

View more resources

Catch up on the very latest B2RLAW
announcements and news here.

04/03/2021

B2RLaw advises PE fund Pinova Capital on the acquisition of software company Raynet GmbH

B2RLaw has advised PE fund Pinova Capital on the Polish aspects of its acquisition of a majority stake of German […]

MORE
02/03/2021

B2RLaw advises Oben Group on its acquisition of plastic packaging group, Poligal

B2RLaw has advised Oben Group on its acquisition of Poligal Group. The acquisition includes BOPP and CPP production plants in […]

MORE
23/02/2021

B2RLaw advises Nuveen Real Estate and Value One on their entry to the Polish student housing market

B2RLaw is advising Eagle JVCo on its acquisition of a portfolio of purpose-built student housing with around 800 beds including […]

MORE
22/02/2021

B2RLaw – No.1 for Venture Capital in CEE in 2020 according to PitchBook

In its first year, B2RLaw has been ranked as the No.1 most active law firm for venture capital in Central […]

MORE
11/02/2021

B2RLaw advises fintech company SMEO on over PLN 21 million VC financing round

B2RLaw has advised FinTech company SMEO on a transaction involving capital injection into the company from international VC fund Finch […]

MORE
05/02/2021

B2RLaw advises on PLN 260 million Krakow residential project

B2RLaw Jankowski Stroiński Zięba & Partners has advised an international real estate developer on the acquisition of a residential project […]

MORE

Get in touch

Not sure who to contact? Let us help you find the right lawyer.

This site uses cookies to improve your experience More information.

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close